Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response

Glucocorticoids such as prednisolone are commonly used in dogs but there is sparse quantitative pharmacokinetic and pharmacodynamic information of this drug in this species. The objective of this study was to quantitatively characterize the concentration-effect relationship for prednisolone in dogs...

Full description

Bibliographic Details
Main Authors: Carl Ekstrand, Helena Pettersson, Ronette Gehring, Mikael Hedeland, Sara Adolfsson, Inger Lilliehöök
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Veterinary Science
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2021.666219/full
id doaj-d5fbe4b3d572448fa576d280d06865eb
record_format Article
spelling doaj-d5fbe4b3d572448fa576d280d06865eb2021-06-09T04:34:04ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692021-06-01810.3389/fvets.2021.666219666219Prednisolone in Dogs—Plasma Exposure and White Blood Cell ResponseCarl Ekstrand0Helena Pettersson1Helena Pettersson2Ronette Gehring3Ronette Gehring4Mikael Hedeland5Mikael Hedeland6Sara Adolfsson7Inger Lilliehöök8Inger Lilliehöök9Division of Pharmacology and Toxicology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, SwedenDivision of Clinical Pathology, Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, SwedenClinical Pathology Laboratory, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, SwedenDivision of Pharmacology and Toxicology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, SwedenDivision of Veterinary and Comparative Pharmacology, Department of Population Health Sciences, Utrecht University, Utrecht, NetherlandsDepartment of Chemistry, Environment and Feed Hygiene, National Veterinary Institute, Uppsala, SwedenDepartment of Medicinal Chemistry, Uppsala University, Uppsala, SwedenDivision of Pharmacology and Toxicology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, SwedenDivision of Clinical Pathology, Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, SwedenClinical Pathology Laboratory, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, SwedenGlucocorticoids such as prednisolone are commonly used in dogs but there is sparse quantitative pharmacokinetic and pharmacodynamic information of this drug in this species. The objective of this study was to quantitatively characterize the concentration-effect relationship for prednisolone in dogs on neutrophil and lymphocyte trafficking and cortisol suppression. Nine beagles, 2–12 years old and part of a group for teaching/research were used in a 4-way crossover experiment including two treatments, active or placebo, administered either per os (PO) or intravenously (IV). Plasma was analyzed for prednisolone and cortisol using ultra-high performance liquid chromatography – tandem mass spectrometry. Leucocyte counts were performed in whole blood. Data was then analyzed by non-linear mixed effect modeling to estimate pharmacokinetic and pharmacodynamic parameters. After administration of prednisolone sodium succinate IV, the typical value (between subject variation) for total body prednisolone clearance was 1,370 ml/h·kg (13.4%). The volumes of the central and peripheral compartment were 2,300 ml/kg (10.7%) and 600 ml/kg (16.0%), respectively. The terminal plasma half-life was 1.7 h. The prednisolone plasma concentration producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%) and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively. The administered dose (1 mg/kg) increased neutrophil and decreased lymphocyte numbers but not over the entire dosage interval of 24 h, due to the short half-life. However, glucocorticoids have a wide range of responses. An anti-inflammatory response due to altered gene transcription might have a longer duration. Future studies on the anti-inflammatory potency together with data presented are needed to optimize future dosage recommendations in dogs.https://www.frontiersin.org/articles/10.3389/fvets.2021.666219/fullcanineglucocorticoidpharmacokineticspharmacodynamicsimmune-suppression
collection DOAJ
language English
format Article
sources DOAJ
author Carl Ekstrand
Helena Pettersson
Helena Pettersson
Ronette Gehring
Ronette Gehring
Mikael Hedeland
Mikael Hedeland
Sara Adolfsson
Inger Lilliehöök
Inger Lilliehöök
spellingShingle Carl Ekstrand
Helena Pettersson
Helena Pettersson
Ronette Gehring
Ronette Gehring
Mikael Hedeland
Mikael Hedeland
Sara Adolfsson
Inger Lilliehöök
Inger Lilliehöök
Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
Frontiers in Veterinary Science
canine
glucocorticoid
pharmacokinetics
pharmacodynamics
immune-suppression
author_facet Carl Ekstrand
Helena Pettersson
Helena Pettersson
Ronette Gehring
Ronette Gehring
Mikael Hedeland
Mikael Hedeland
Sara Adolfsson
Inger Lilliehöök
Inger Lilliehöök
author_sort Carl Ekstrand
title Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
title_short Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
title_full Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
title_fullStr Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
title_full_unstemmed Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
title_sort prednisolone in dogs—plasma exposure and white blood cell response
publisher Frontiers Media S.A.
series Frontiers in Veterinary Science
issn 2297-1769
publishDate 2021-06-01
description Glucocorticoids such as prednisolone are commonly used in dogs but there is sparse quantitative pharmacokinetic and pharmacodynamic information of this drug in this species. The objective of this study was to quantitatively characterize the concentration-effect relationship for prednisolone in dogs on neutrophil and lymphocyte trafficking and cortisol suppression. Nine beagles, 2–12 years old and part of a group for teaching/research were used in a 4-way crossover experiment including two treatments, active or placebo, administered either per os (PO) or intravenously (IV). Plasma was analyzed for prednisolone and cortisol using ultra-high performance liquid chromatography – tandem mass spectrometry. Leucocyte counts were performed in whole blood. Data was then analyzed by non-linear mixed effect modeling to estimate pharmacokinetic and pharmacodynamic parameters. After administration of prednisolone sodium succinate IV, the typical value (between subject variation) for total body prednisolone clearance was 1,370 ml/h·kg (13.4%). The volumes of the central and peripheral compartment were 2,300 ml/kg (10.7%) and 600 ml/kg (16.0%), respectively. The terminal plasma half-life was 1.7 h. The prednisolone plasma concentration producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%) and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively. The administered dose (1 mg/kg) increased neutrophil and decreased lymphocyte numbers but not over the entire dosage interval of 24 h, due to the short half-life. However, glucocorticoids have a wide range of responses. An anti-inflammatory response due to altered gene transcription might have a longer duration. Future studies on the anti-inflammatory potency together with data presented are needed to optimize future dosage recommendations in dogs.
topic canine
glucocorticoid
pharmacokinetics
pharmacodynamics
immune-suppression
url https://www.frontiersin.org/articles/10.3389/fvets.2021.666219/full
work_keys_str_mv AT carlekstrand prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT helenapettersson prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT helenapettersson prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT ronettegehring prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT ronettegehring prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT mikaelhedeland prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT mikaelhedeland prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT saraadolfsson prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT ingerlilliehook prednisoloneindogsplasmaexposureandwhitebloodcellresponse
AT ingerlilliehook prednisoloneindogsplasmaexposureandwhitebloodcellresponse
_version_ 1721389335551410176